The new guidelines cover prevention and early diagnosis of chronic conditions, such as diabetes and heart disease, and provide evidence-based primary care interventions for people living with HIV. The guidelines also focus on caring for women and children with HIV, making them a valuable resource for a wide range of healthcare providers.
The Lancet editorial argues that criticism of President Bush's AIDS spending is necessary to ensure efficient use of limited resources. Leading scientists and public-health advocates have judged that the size of US investment into AIDS renders President Bush immune from criticism, but this assessment is mistaken.
A recent study found that HIV clinicians with fatalistic attitudes are less likely to provide prevention counseling to HIV-positive patients. The study surveyed 618 patients and found a correlation between provider fatalism and reduced reporting of prevention services.
The HIV Structural Reference Database will aid in developing strategies to inhibit HIV protease activity and understand mutations that make the virus resistant to certain drugs. The database contains annotated structural data from published literature and laboratory contributions.
Young men in rural Malawi associate HIV with masculinity and engage in risky behavior to demonstrate virility. This misunderstanding of AIDS risk has significant implications for future research and HIV prevention education.
Researchers at Michigan State University have devised new ways to understand the impact of AIDS on families in rural Africa. The study shows that the disease is not always devastating, but rather cripples some families while leaving others with a better chance of enduring.
The Lancet discusses new design changes to the journal, including open-access policies and electronic document posting. The article also explores various HIV/AIDS strategies for developing countries, including expanded access to treatment and prevention efforts. Researchers emphasize the importance of local solutions and community-led ...
Researchers have made progress in understanding the mechanisms of HIV drug resistance, particularly with tenofovir and the DAPY compounds. These drugs approach the problem of resistance in different ways, targeting reverse transcriptase enzyme or molecular machine used by the AIDS virus.
A study of 374 people with HIV-1 infection found that CMV-positive status was significantly associated with accelerated progression to AIDS and death. Randomised clinical trials are needed to investigate the role of CMV in HIV disease progression.
Nigerian naval personnel are putting themselves and their partners at risk by denying the existence of AIDS and engaging in risky sexual behaviors. A recent survey found that nearly half of sailors had sex with a female sex worker without using a condom, despite having good knowledge of AIDS-related information.
A new study will evaluate the effectiveness of a face-to-face support group for older adults with depression and HIV/AIDS. The intervention aims to improve coping mechanisms, quality of life, and social support.
A Temple virologist has received a grant to investigate the role of macrophages in HIV dementia complex. The researcher aims to understand how these cells contribute to the development of the condition, which affects 10% of AIDS patients, and explore potential therapies to target them.
Researchers at the Salk Institute have made a breakthrough in understanding how HIV replicates within host cells. The study revealed that molecules exist in cells that help convert HIV's RNA genome to DNA, allowing for the production of new virus particles.
The Case CFAR, located in the Midwest, has been renewed with an $8 million NIH award for a five-year period. This renewal recognizes the center's strong AIDS research program and its collaboration with local and international institutions.
A recent study found that HIV infection progresses to AIDS at a rate of 7.4 years in developing countries, compared to 11 years in Western developed nations. The study also revealed a higher mortality rate among men living in developing countries.
Researchers sequenced genetic material from a new strain of SIV in chimpanzees near Kisangani, Democratic Republic of Congo. The new strain is not related to HIV-1 and confirms that HIV-AIDS did not originate from oral polio vaccines.
The Indiana University-Kenya AIDS program has received an expanded grant, allowing for the treatment of up to 15,000 HIV-infected individuals in rural communities. The new funding will also establish two additional rural programs and support educational initiatives for medical students and providers.
Researchers at Mayo Clinic implant human blood stem cells into fetal pigs, revealing the presence of hybrid cells with both human and pig DNA. These findings may help explain how viruses jump from animals to humans, paving the way for discovery about disease origins like AIDS.
Researchers found that a combination of ZDV, 3TC, and EFV was the most successful initial treatment regimen, with participants experiencing delayed failure and faster viral load suppression. However, using four drugs in combination did not prove more effective than sequential three-drug regimens, but did delay failure longer.
A new global study on HIV/AIDS indicates the effectiveness of needle and syringe exchange programmes for preventing HIV transmission among people who inject drugs. Distribution of sterile needles and syringes helps reduce HIV infection rates, with cities introducing exchanges seeing a 19% decrease in prevalence.
A study by Case Western Reserve University researchers found that human beta defensins 2 and 3 in the mouth's lining can inhibit HIV-1 replication and regulate viral receptors. This discovery has potential for developing new medical interventions using natural products to prevent HIV infection, particularly in high-risk areas.
A laboratory study found that methylnaltrexone blocked increases in HIV entry and replication when immune cells are exposed to therapeutic doses of morphine. The study suggests that the drug may improve care for patients with AIDS who require pain relief, potentially reducing the risk of severe constipation.
A new study found that forgiving others and feeling forgiven were associated with fewer depressive symptoms, life stressors, and improved quality of life. Expressing forgiveness in the context of HIV infection also decreased the likelihood of placing others at risk.
Researchers found that total lymphocyte count and hemoglobin concentration decline rapidly in individuals who develop AIDS, with over 77% of study participants exhibiting these declines. This finding offers an alternative to current HIV diagnosis methods, which require expensive technology and equipment.
A new study has found that a phone support group program helps older adults with HIV/AIDS develop coping skills, reducing stress and suicidal thoughts. The 12-week telephone intervention program appealed to participants who faced barriers in accessing traditional support groups or counseling services.
Researchers found that a 6-month mark after starting antiretroviral therapy (HAART) can be used to predict disease progression in HIV/AIDS patients. Patients with higher CD4 cell counts and lower viral loads have lower risks of AIDS or death at this stage, suggesting that initial response to treatment is crucial for determining prognosis.
Purdue University chemist Jean Chmielewski has won a national award for developing new compounds that disrupt the AIDS virus's ability to reproduce. Her approach involves creating molecular 'wedges' that block HIV proteins from binding together, promising initial results in testing with infected cells.
Researchers found that the HIV vpr gene exploits the normal repair process of cells to stop vital white blood cells from replicating, thus disabling the immune system. The study suggests a possible treatment for AIDS-related immune-system damage using medicines that prevent the human ATR gene from being activated by HIV's vpr gene.
A new grant of US$41 million from the Global Fund will support HIV/AIDS treatment and prevention in South Africa over 2 years. Generic antiretrovirals will be developed and produced locally, offering affordable access to life-saving medications.
Researchers at Ohio State University found that endostatin can stop Kaposi's sarcoma cells from growing new blood vessels and migrating through the body. The study suggests a controlled release of endostatin could be an effective treatment option for patients with KS.
Researchers have developed a new herpes-based AIDS vaccine that could help the immune system produce more infection-fighting antibodies and killer T-cells, potentially making it more effective. The vaccine uses an amplicon to deliver DNA from the AIDS virus, which is then amplified and used to trigger an immune response.
A study published in the journal AIDS found that HAART therapy can significantly prolong survival for AIDS patients with central nervous system lymphoma, with median survival of at least 22 months. This is a significant finding, as previously diagnosed patients had only a few weeks to months after diagnosis.
The WHO 2003-2008 programme focuses on controlling HIV/AIDS, with a goal of 3 million people in developing countries receiving antiretroviral treatment by 2005. The initiative also aims to strengthen health systems and secure political backing for investment.
The Lancet appoints Dr. Tobias to a $15 billion programme tackling AIDS in African and Caribbean countries most devastated by the pandemic. Critics argue that his lack of knowledge about Africa and connections to the pharmaceutical industry may compromise his credibility.
Researchers found that rare variations of HLA-A and HLA-B genes can protect against HIV. The study, which analyzed data from 996 HIV-infected men in Chicago, suggests that these genetic variants may be used to develop targeted AIDS vaccines.
A study of 9800 patients in Europe, Israel, and Argentina found that HAART significantly reduced AIDS incidence by 50%, with a 40% reduction in deaths among patients with low CD4 counts. Long-term follow-up is essential to observe changing causes of morbidity and mortality.
A new study published in Nature Medicine has found that certain human genes can predict the progression rate of AIDS in infected individuals. The researchers analyzed data from a large group of homosexual men with HIV and found that those with specific HLA protein types were more likely to succumb to the disease quickly.
A structured stop-and-start drug regimen could extend care to more patients in resource-poor countries while reducing HIV drug toxicity. However, the high cost of drugs needed for the study poses a significant challenge to its success.
India's HIV prevalence rate is less than 1 percent, but a looming pandemic on the horizon due to shifting demographics and changing cultural values. The researchers recommend targeted prevention programs for high-risk groups, such as prostitutes and men who have sex with men, and offer circumcision as an additional avenue of prevention.
Researchers found that AIDS-related lymphomas responding well to chemotherapy have high levels of proteins indicating rapid growth and multidrug resistance. The study also showed that suspending antiretroviral therapy during lymphoma treatment is safe and allows for high overall survival.
Researchers Barany and Hammett found that forests and non-timber forest products are crucial for household coping strategies, offering low-cost alternatives to meet nutritional needs. Medicinal plants from these resources can treat conditions related to HIV/AIDS, making them a vital priority for conservation and management efforts.
The Vanderbilt Meharry Developmental Center for AIDS Research aims to advance treatment and prevention of HIV/AIDS through collaboration and education. The center will focus on racial disparities and minority populations, building on existing collaborations between the two institutions.
Researchers identify a helpful gene mutation in the Vpr gene of long-term nonprogressive HIV patients, which impairs the HIV virus' cell-killing machinery. The presence or absence of this mutation may play a central role in determining which patients develop fatal AIDS.
A study found that HAART reduced the risk of visual impairment and improved quality of life for AIDS patients. Patients who received HAART had a lower incidence of visual acuity loss compared to those who did not, especially those with substantial improvement in their immunity.
The editorial emphasizes that providing affordable drugs is insufficient to combat HIV in the developing world. Comprehensive medical care, including training for healthcare workers and laboratory tests, must also be included to make Highly Active Antiretroviral Therapy (HAART) effective.
The editorial highlights China's slow information-gathering from rural districts and secretive attitude to national health statistics as major challenges. A concerted effort to compile accurate statistics on HIV/AIDS prevalence could demonstrate China's ability to learn from its mistakes and acknowledge global responsibilities.
The GSK Drug Discovery and Development Research Grant Program provides funding for innovative research into HIV/AIDS treatments. Researchers will be selected based on the potential importance of their project, originality, and ability to conduct the proposed research.
Researchers studied sooty mangabey monkeys infected with SIV, finding they didn't get sick like humans with HIV. The lack of symptoms was attributed to low-level immune system responses and ability to maintain T cell renewal.
The Bush administration is considering implementing a pro-life policy that would restrict foreign non-governmental organizations from receiving US funds if they provide abortions or lobby for abortion liberalization. This policy threatens the $15 billion HIV/AIDS fund, which relies on local clinics providing family-planning and materna...
The US has pledged $1 billion to combat HIV/AIDS in 14 high-prevalence countries. The programme aims to prevent 7 million new infections, treat 2 million people, and support 10 million infected individuals.
Researchers studying sex workers on the US-Mexico border found that many have unprotected sex with tourists and truck drivers from the Midwest. The study highlights the potential for these interactions to spread HIV/AIDS among vulnerable populations.
The Emory Center for AIDS Research (CFAR) has received a five-year grant from the National Institutes of Health to further HIV/AIDS research and prevention efforts. With $33.5 million in NIH funding, the CFAR will build on recent advances in immunology, vaccines, and drug development.
A study estimates that US HIV prevention efforts saved between 204,000 to 1.585 million lives and resulted in cost savings of at least $11 billion since the onset of the epidemic, with a cost per infection prevented ranging from under $50,000 to $6,400.
The NIH has awarded a $4.6 million grant to Rutgers University to develop new and effective drugs for AIDS. The five-year program will use structure-based drug design to identify proteins involved in HIV transmission and develop inhibitors that can overcome drug resistance.
The AIDS and Cancer Specimen Bank at UCSF is expanding its operations with new technologies and a central coordinating office. The bank now serves over one million specimens from around the world, including China, Thailand, and South America.
The new CIPRA grant will address HIV/AIDS as a family issue, not just an individual problem. The research aims to develop practical techniques tailored to the needs of South African families, with a focus on prevention, treatment, and social support services for those living with HIV/AIDS.
UCSF's Institute for Global Health has been awarded $4.5 million by the CDC to assist in global AIDS programs, focusing on training, technical assistance, and research in resource-constrained countries. The consortium will also establish regional coordinating centers in Brazil, India, and Zimbabwe.
Researchers Irwin Chaiken, Nouri Neamati, Alan C. Sartorelli, Nan-Sook Lee, Elias Lolis, and Min Lu received awards for their work on preventing HIV from infecting host cells, developing integrase inhibitors, and making current drugs more effective. The $500,000 award aims to encourage new approaches in HIV/AIDS therapy research.
Scientists have gained valuable insights into AIDS by studying the simian immunodeficiency virus in monkeys. Researchers are now exploring ways to vaccinate against HIV transmission and eliminate latent viruses.
The incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma declined sharply in the mid-1990s, mainly due to AIDS treatment improvements. However, non-AIDS-associated non-Hodgkin's lymphoma incidence has continued to rise.